Mannkind and United Therapeutics are creating an inhaled formulation of ralinepag, an experimental oral PAH treatment.

Treatment with treprostinil led to significant and sustained improvements in children with PH associated with lung disease, ...

Corvista Health and Mayo Clinic will study whether Corvista-PH can improve pulmonary hypertension diagnosis and referrals.

“This study provides comprehensive preclinical evidence that the novel PDE5 inhibitor CPD1 is a potent therapeutic candidate ...

The analysis revealed dozens of genes with abnormal expression in cells from people with idiopathic PAH, and the researchers ...

World Pulmonary Hypertension Day 2026 highlights hope through clinical trials for the global disease community.

Pulmonary hypertension (PH) is caused by high blood pressure in the lungs, which is caused by narrowed and thickened pulmonary arteries. Because of the added effort needed to pump blood through the ...

Although there is no cure yet for pulmonary hypertension (PH), there are a variety of therapies available that can help manage the symptoms of the disease and maintain or improve the quality of life ...

Share this page with email Share this page on Facebook Share this page on X Share this page on Reddit Print Preferred Source on Google A clinical trial testing mosliciguat, an inhaled therapy for ...

Treatment with mosliciguat, an inhaled medication given once-daily for pulmonary hypertension (PH), can safely reduce the resistance against blood flow in blood vessels of the lungs, according to a ...

Pulmonary hypertension (PH) is a rare but severe health condition characterized by high blood pressure in the pulmonary arteries. It is diagnosed when the arteries that transport blood from the heart ...

In a large clinical trial, treatment with Winrevair (sotatercept-csrk) significantly reduced pressure in the lungs’ blood vessels among adults with a form of pulmonary hypertension associated with ...